X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Moderate Buy” by Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $9.3750.

A number of brokerages have issued reports on XFOR. Guggenheim began coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Leerink Partners initiated coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st.

X4 Pharmaceuticals Trading Up 5.2%

NASDAQ:XFOR opened at $4.23 on Tuesday. The company has a fifty day moving average of $4.08 and a 200 day moving average of $3.92. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.83. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $398.97 million, a P/E ratio of -0.93 and a beta of 0.34.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. On average, research analysts predict that X4 Pharmaceuticals will post -0.77 earnings per share for the current year.

Institutional Trading of X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of XFOR. Empery Asset Management LP purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth about $35,804,000. Perceptive Advisors LLC purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth about $25,258,000. Bain Capital Life Sciences Investors LLC grew its position in shares of X4 Pharmaceuticals by 227.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock worth $31,870,000 after buying an additional 5,530,866 shares during the period. Kalehua Capital Management LLC purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth about $14,891,000. Finally, Braidwell LP purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth about $13,476,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.